Stemline Therapeutics Inc (NASDAQ:STML) has been given a $34.00 target price by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 300.00% from the stock’s current price.

A number of other equities analysts have also recently issued reports on the company. Zacks Investment Research cut Stemline Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 18th. Wedbush restated an “outperform” rating and set a $15.00 price target on shares of Stemline Therapeutics in a report on Tuesday, December 6th. Cowen and Company restated a “buy” rating on shares of Stemline Therapeutics in a report on Thursday, February 2nd. Ladenburg Thalmann Financial Services restated a “buy” rating on shares of Stemline Therapeutics in a report on Monday, February 6th. Finally, Jefferies Group LLC set a $16.00 price target on Stemline Therapeutics and gave the stock a “buy” rating in a report on Friday, February 3rd. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Stemline Therapeutics has a consensus rating of “Buy” and a consensus price target of $24.33.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Shares of Stemline Therapeutics (NASDAQ:STML) traded up 1.76% during trading on Monday, hitting $8.65. The stock had a trading volume of 100,430 shares. The firm has a 50 day moving average price of $7.79 and a 200-day moving average price of $10.60. Stemline Therapeutics has a 52 week low of $4.06 and a 52 week high of $14.60. The stock’s market capitalization is $155.28 million.

TRADEMARK VIOLATION WARNING: “HC Wainwright Reiterates $34.00 Price Target for Stemline Therapeutics Inc (STML)” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at http://www.dailypolitical.com/2017/03/20/stemline-therapeutics-inc-stml-receives-buy-rating-from-hc-wainwright.html.

In other news, CEO Ivan Bergstein sold 17,980 shares of the company’s stock in a transaction that occurred on Tuesday, February 28th. The stock was sold at an average price of $6.99, for a total transaction of $125,680.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, COO Kenneth Hoberman sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, February 27th. The stock was sold at an average price of $6.97, for a total value of $27,880.00. The disclosure for this sale can be found here. Insiders have sold 65,356 shares of company stock worth $531,879 over the last ninety days. 16.70% of the stock is owned by insiders.

Institutional investors have recently modified their holdings of the company. Perceptive Advisors LLC purchased a new position in shares of Stemline Therapeutics during the fourth quarter worth $115,000. Ladenburg Thalmann Financial Services Inc. raised its position in shares of Stemline Therapeutics by 810.6% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 12,694 shares of the biopharmaceutical company’s stock worth $136,000 after buying an additional 11,300 shares during the last quarter. Oak Ridge Investments LLC raised its position in shares of Stemline Therapeutics by 26.3% in the third quarter. Oak Ridge Investments LLC now owns 12,796 shares of the biopharmaceutical company’s stock worth $139,000 after buying an additional 2,663 shares during the last quarter. State Treasurer State of Michigan purchased a new position in shares of Stemline Therapeutics during the third quarter worth $217,000. Finally, Acadian Asset Management LLC purchased a new position in shares of Stemline Therapeutics during the third quarter worth $400,000. 37.76% of the stock is currently owned by institutional investors.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

5 Day Chart for NASDAQ:STML

Receive News & Ratings for Stemline Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.